MedTrace Logo

Memantine and Comprehensive, Individualized Management of Alzheimer's Disease and Caregiver Training

NCT00120874 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2016-10-25

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether a comprehensive, individualized management approach with caregiver training and medication with memantine will alleviate symptoms in community dwelling patients with moderate to severe Alzheimer's disease.

Conditions

Interventions

BEHAVIORAL

Individualized management of AD including caregiver training

Individualized management program: consists of home visits to get the patient exercising, doing enjoyable activities and cognitive stimulation, educational sessions for caregivers on coping with difficult situations and a caregiver support group to help with questions and emotional concerns.

DRUG

Memantine

Patients receive 10 milligrams of memantine twice daily.

Sponsors & Collaborators

  • Forest Laboratories

    collaborator INDUSTRY

  • Fisher Center for Alzheimer's Research Foundation

    collaborator OTHER

  • NYU Langone Health

    lead OTHER

Principal Investigators

  • Barry Reisberg, M.D. · NYU Langone Health

  • Sunnie Kenowsky, D.V.M. · NYU Langone Health

Study Design

Allocation
RANDOMIZED
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-08-31
Primary Completion
2011-11-30
Completion
2011-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00120874 on ClinicalTrials.gov